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Abstract 6-l.-(ru-Aminoadipoyl)-L-cysteinyl-o-valine (ACV) 
synthetase catalyses the formation of the common precursor 
tripeptide of both the penicillin and cephalosporin antibiotics from 
the L-enantiomers of its constituent amino acids. Replacement of 
cysteine with r.-O-methylserine in preparative-scale incubations 
led to the isolation of both L-O-methylserinyl+valine and L-O- 
methylserinyl-o-valine dipeptides. The dipeptides were character- 
ized with the aid of authentic synthetic standards by both ‘H 
NMR and electrospray ionization MS. A revised mechanism for 
ACV biosynthesis involving formation of the cysteinyl-valine 
peptide bond before the epimerisation of valine and subsequent 
condensation with the Scarboxyl of L-cu-aminoadipate is there- 
fore proposed. 
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1. Introduction 
The biosynthesis of &L-(a-aminoadipoyl)-L-cysteinyl-D-val- 
ine (ACV), the common precursor of the penicillin and cepha- 
losporin antibiotics, is catalysed by a single multifunctional 
enzyme, ACV synthetase, which has been isolated from several 
sources [la]. On the basis of several properties of the enzyme 
and its sequence identity to previously described peptide syn- 
thetases it is evident that it is a member of this class of large 
multifunctional enzymes [5]. A general ‘thiol template’ mecha- 
nism has been proposed for the peptide synthetases [6]. In this 
proposal the carboxyl groups of the substrate amino acids are 
activated by formation of their respective aminoacyladenylates 
[2] and the aminoacyl groups are then proposed to be trans- 
ferred to an enzyme-bound thiol. Indeed ACV synthetase from 
Cephulosporium ucremonium has been shown to catalyse sub- 
strate amino acid-dependent ATP-PP, exchange reactions in 
response to all three natural substrates and some substrate 
analogues [5,7]. In the case of L-cl-aminoadipate activation the 
activity was rather labile and could not be detected at all for 
the enzyme isolated from Streptomyces clavuligerus ([5]; 
Byford, M.F. and Shiau, C.-Y., unpublished observations). The 
thiol template mechanism also postulates the translocation of 
the enzyme-bound amino acid thioesters and the dipeptide in- 
termediate by (a) 4’-phosphopantetheine cofactor(s) [6] and 
ACV synthetase contains 4’-phosphopantetheine [8]. For ACV 
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synthesis, the thiol template mechanism invokes the formation 
of the peptide bond between the &carboxyl of L-a-aminoadi- 
pate and the amino group of L-cysteine prior to that formed 
between L-cysteine and valine. Epimerisation of the valine res- 
idue is postulated to occur at the valinyl thioester stage as this 
is a rationale for the observed activation of the valine carboxyl 
which is not involved in peptide bond formation [2]. Evidence 
for aminoacyl groups covalently bound to the enzyme via thioe- 
sters was qualitatively assessed by release of labelled valine 
from the enzyme after treatment with performic but not formic 
acid [2]. A summary scheme for the thiol template mechanism 
for ACV synthesis is shown in Scheme I. Compared with most 
of the members of the peptide synthetase family, ACV synthe- 
tase is relatively small (420 kDa, based on translation of the 
nucleotide sequence [9]) and catalyses comparatively few reac- 
tions: minimally the formation of two peptide bonds and the 
epimerisation of the valine residue. Thus, ACV synthetase may 
serve as a useful model system for non-ribosomal peptide syn- 
thesis. 
Recently, we reported results on the substrate specificity of 
ACV synthetase from C. acremonium [7]. Potential substrates 
were initially screened using both the ATP-PP, exchange assay 
and the incorporation of [‘?J]cysteine and [‘4C]valine into po- 
tential tripeptide products. Based on these results, we at- 
tempted the preparative-scale conversion of several analogues 
of L-a-aminoadipate, L-cysteine, and L-valine into tripeptides. 
Incubations with L-S-carboxymethylcysteine in place of a-ami- 
noadipate. both L-vinylglycine and I_-allylglycine in place of 
cysteine, and L-u//o-isoleucine in place of valine, produced suf- 
ficient tripeptide for the isolation and characterization of 
L-((:v.steine-S-ucetJ$L-cysteinyl-o-valine, L-&(aminoadipoyl)+- 
Vin~~lgl~~inyl-D-valine, L-&(aminoadipoyl)-L-ul/#ycin.&o-val- 
ine and I_-&(aminoadipoyl)-I.-cysteinyl-o-i.s&ucine, respec- 
tively. In several other cases in which the ‘“C incorporation 
assay had indicated the formation of potential peptide product 
and for which there was detectable substrate analogue-depend- 
ent ATP-PP, exchange, we were unable to detect any of the 
anticipated L.L,D tripeptide product when the HPLC effluent 
was screened by ‘H NMR (500 MHz). In particular, when 
O-methyl serine was used as a substitute for cysteine, assays for 
peptide formation using [‘4C]valine incorporation showed an 
apparent rate that was 75% that observed for cysteine itself. 
Despite the availability of authentic 6-L-(cl-aminoadipoyl)-L-O- 
methylserinyl-o-valine we were unable to detect the biosynthe- 
sis of this tripeptide. Although, as discussed in detail in [7]. 
other explanations for these apparently conflicting results are 
possible, we postulate that the 0-methylserinyl-[“‘Clvaline 
dipeptide(s) might be produced in the incubations. 
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2. Experimental 
2.1. General 
C. acremonium ACV synthetase was prepared as described previously 
[lo], routinely through the Superdex S-200 stage. ATP-PP, exchange 
assays, ‘H NMR (500 MHz) and electrospray ionization MS analyses 
were done as in 171. 6-L-(a-Aminoadipoyl)-L-0-methylserinyl-o-valine, 
L-(0-methylserinyl)-L-valine and L-(O-methylserinyl)-D-valine were 
synthesized by standard solution-phase methods and their structures 
confirmed by ‘H NMR (500 MHz) and electrospray ionization MS 
(Table 1). 
2.2. Enzymic prepuration of’O-methylswine-valine dipeptidrs 
Incubations including the cysteine analogue 0-methylserine (5 mM) 
in the presence of L-a-aminoadipic acid (5 mM) and L-valine (5 mM) 
were carried out as in [7] for the preparative scale enzymic synthesis of 
tripeptides, except that the incubations were terminated by addition of 
acetone (40% v/v, final concentration). After removal of the protein by 
centrifugation (13,000 rpm, 5 min) the acetone was removed in vacua 
and the supernatant dried in vacua. The residue was dissolved in water 
(approx. 1 ml). L-[2-2H]Valine or [l-‘3C]valine replaced L-valine when 
required. 
For incubations containing L,L-0-methylserinyl-valine the reaction 
mixture contained MgCl, (65.6 mM), L-a-aminoadipic acid (5.0 mM), 
L,L-0-methylserinyl-valine (trifluoroacetate salt) 1.1 mM, valine (5.0 
mM), dithiothreitol (3.0 mM), ATP (26.6 mM), enzyme preparation 
(400~1, total synthetase activity up to 100-150 pkat) in Tris-HCl buffer 
(50 mM, pH 7.5) in a final volume of 8OOpl and was carried out at 27°C 
for 16 h. The isolation of both diastereoisomers followed the protocol 
described below. 
2.3. Isolation of 0-methylserinyl-valine dipeptidrs 
The protocols were developed using authentic synthetic standards. 
Appropriate aliquots of the aqueous fraction obtained as detailed 
above were injected onto a reverse-phase ODS column (Hypersil C,, 
4.6 x 250 mm) and eluted with 21 mM NH,HCO, in 15% (v/v) aq. 
methanol. The flow rate used was 1 ml/min. The fraction containing the 
desired dipeptide (retention vol. 5.9 ml) was freeze-dried. The residue 
was dissolved in water (1 ml) and acidified to pH 2-3 with a minimum 
amount of approx. 0.1 M aqueous HCl. To remove residual glycerol, 
the acidic solution was loaded to a pre-washed Dowex 5OW-X8 column 
(1 ml). The loaded column was washed with water (20 ml) and then 
eluted with 2 M NH,OH (25 ml). The NH,OH fraction was freeze-dried 
and the residue was dissolved in water (0.3 ml). This sample was re- 
chromatographed on reverse phase HPLC with an ODS column (Hy- 
persil C,*, 4.6 x 250 mm), using a linear gradient. The procedure was 
developed using authentic synthetic standards. The mobile phase con- 
sisted of two eluants: solvent (A) 25 mM aq. NH,HCOI and solvent (B) 
was obtained by the addition of 15% (v/v) methanol to solvent (A). The 
linear gradient used was: 0% B at zero time to 60% (v/v) B at 20 min 
returning to 0% B at 23 min. The flow rate was 1 ml/min. Retention 
vol. of L,L-0-methylserinyl-valine 18.7 ml: retention vol. of L,D-O-meth- 
ylserinyl-valine 19.5 ml. 
3. Results 
Protocols for the isolation and separation of the diastereoi- 
Somers L-0-methylserinyl-L-valine and L-O-methylserinyl-o- 
valine were developed with the aid of authentic synthetic stan- 
dards. Fig. la shows clearly that instead of the anticipated 
tripeptide, both the L,L dipeptide (L-0-methylserinyl-L-valine) 
and the L,o-dipeptide (L-O-methylserinyl-o-valine) were pro- 
duced by ACV synthetase in incubations containing L-a-amino- 
adipate, L-0-methylserine and L-valine. Although yields of the 
dipeptides were low (<0.25%), sufficient material was isolated 
from a 16 h incubation to determine the anticipated structures 
by both ‘H NMR (500 MHz) and electrospray ionization MS 
(Table 1). The low final yield of the separated diastereoisomers 
reflects a strategy pooling the HPLC effluent for maximum 
purity of each isomer rather than for maximum yield (Fig. lb). 
E- S-CYS-AAA 
__________________.-_________ 
EPIMERISATION 
E- S-(D)-VAL-CYS-AAA 
Hz0 L,I&ACV 
Scheme 1. The ‘thiol-template’ mechanism for ACV synthetase. AAA, 
a-aminoadipate; (Xaa-AMP), aminoacyladenylate of amino acid Xaa; 
E--, covalently bound pantetheinate cofactor. Independent sites for 
the aminoacyladenylation, epimerisation and thioesterase partial reac- 
tions are shown boxed (dashed lines). 
The identities of the two products were confirmed un- 
ambiguously by doping the biosynthetic products with the 
authentic standards followed by ‘H NMR (500 MHz) analysis. 
Any possibility of contamination of the biosynthesized samples 
by trace amounts of the authentic compounds in the HPLC 
system was eliminated by biosynthesis of the dipeptides from 
[l-‘3C]valine and confirmation of its incorporation by electro- 
spray MS (Table 1). 
The ratios of the formation of the L,L- and L,o-dipeptides 
were somewhat variable depending on the enzyme preparation 
used but were typically approximately I : 1. Biosynthesis of the 
dipeptides from [2-‘Hlvaline resulted in the formation of deu- 
terated L,L dipeptide which could be characterized. Insufficient 
L,D dipeptide was obtained for characterization, as in this case 
the ratio of the L,L to L,D diastereoisomer was estimated from 
the HPLC analysis as > IO: 1 (Fig. lc). Since the diastereoisom- 
ers were formed in approximately equal yield by the same 
enzyme preparation with unlabelled valine as a substrate, a 
primary deuterium kinetic isotope effect would appear to be 
operating in the epimerisation process. Yields of both diaster- 
eoisomers were decreased significantly when L-ol-aminoadipate 
was omitted from the incubation. No conversion of authentic 
L,L-dipeptide to the L,D form was seen when it was incubated 
with ACV synthetase, indicating that the L,L form is not a free 
intermediate in the synthesis of the L,D dipeptide. Neither the 
L,L nor L,D 0-methylserinyl-valine dipeptide stimulated the 
ATP-PP, exchange reaction (not shown), indicating that nei- 
ther dipeptide was able to be reactivated as a weak analogue 
of valine and form a dipeptide aminoacyladenylate. 
4. Discussion 
We have demonstrated previously [7] that the substrate spec- 
ificity of ACV synthetase is comparatively broad, since the 
enzyme can synthesize tripeptides where each of the natural 
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Table 1 
Electrospray ionization MS analysis of authentic and biosynthesized 0-methylserinyl-valine dipeptides 
Entry Dipeptide % observed at m/z (MH’) 
Synthetic (L,L)-0-methylserinyl-valine 0 100 13 0 0 0 
n Synthetic (L,D)-O-methylserinyl-vahne 0 100 11 2 4 0 
b Biosynthetic (L,L) (L,D) O-methylserinyl-vahne + 0 100 12 2 0 0 
‘ Biosynthetic (L,L) + (L,D) 0-methylserinyl-[l-‘3C]vahne 0 4 100 14 3 1 
d Biosynthetic (L,L) 0-methylserinyl-[2-2H]vahne 1 4 100 17 3 4 
’ Synthetic standards. 
bBiosynthesized dipeptides (analysed as a mixture of diastereoisomers) from the incubation of L-valine and L-0-methylserine. 
’ Biosynthesized dipeptides (analysed as a mixture of diastereoisomers) from the incubation of L-[I-“Clvaline and t.-O-methylserine. 
’ Biosynthesized L,L-dipeptide from the incubation of L-[2-‘Hlvaline and L-U-methylserine. 
substrates is replaced by a structural analogue. However, dur- 
ing the initial screening process for potential substrate ana- 
logues we noticed that some analogues significantly stimulated 
ATP-PP, exchange but we were unable to isolate a tripeptide 
product. We reasoned that this could be due to the analogue 
being discriminated against in a subsequent step in the catalytic 
sequence. Similarly, we reasoned that the apparently significant 
incorporation of [‘4C]valine into putative peptide products in 
incubations done in the presence of substrate analogues (e.g. 
O-methylserine), which also stimulated ATP-PP, exchange. 
might be due to the formation of dipeptide product(s), which 
could reflect an inability of the enzyme to complete tripeptide 
formation from an analogue of the natural dipeptide intermedi- 
ate. 
The results presented in this paper demonstrate clearly that, 
at least in the case of L-O-methylserine, a dipeptide is indeed 
produced in detectable amounts by ACV synthetase even in the 
presence of L-a-aminoadipate. Furthermore, both the L,L and 
L,D diastereoisomers were produced. This presumably reflects 
incomplete epimerisation of the valine residue at the dipeptide 
stage, particularly since recovery of the epimerised product 
decreased significantly when [2-*H]valine was used as the sub- 
strate. Thus, the epimerisation of the vahne residue occurs after 
the formation of the first peptide bond (although with sub- 
strates forming tripeptides it may occur at the tripeptide stage). 
Surprisingly, the recovered dipeptide is an analogue of cys- 
teinyl-valine and not an analogue of a-aminoadipoyl-cysteine 
as would be expected from the conventional thiol template 
mechanism. All attempts to isolate detectable amounts of ~-a- 
aminoadipoyl-L-cysteine from preparative incubations have 
thus far been unsuccessful. 
These two key observations are inconsistent with previous 
mechanistic proposals for ACV synthetase. Previously, it has 
been suggested that the epimerisation occurs on a postulated 
enzyme-bound valinyl thioester intermediate in accord with 
studies on e.g. gramicidin and tyrocidin biosynthesis [l I] where 
the inversion of configuration is completely reversible and oc- 
curs prior to the insertion of the o-residue into the peptide 
chain. Work on actinomycin D, which contains an internal 
o-vahne residue, has shown that the enzyme actinomycin syn- 
thetase II assembles the first three residues of the peptide lac- 
tone chain of 4-methyl-3-hydroxyanthraniloyl+threonyl-o- 
valinyl-~-prolyl-~-(N-methyl)glycinyl-~-(~-methyl)valine. Very 
recently, Stindl and Keller [12] have shown that both 4-methyl- 
3-hydroxyanthraniloyl-L-threonyl-L-valine and 4-methyl-3-hy- 
droxyanthraniloyl-L-threonyl-o-vahne are enzyme-bound in- 
termediates, and they suggest that the former is an obligatory 
intermediate in the synthesis of the latter. These authors also 
proposed that epimerisation at the peptide stage may be a 
general mechanism for peptide synthetases which catalyse for- 
mation of peptides containing o-amino acids at positions other 
than at the N-terminus. The production of L,L- and L,o-dipep- 
tides by ACV synthetase when incubated with O-methylserine 
provides independent support for this proposal, derived from 
another peptide synthetase and determined using different tech- 
AB 
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C 
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(b) 
Cc) 
Fig. 1. Separation of L-0-methylserinyl-L-valine and L-O-methylserinyl- 
b-valine by reverse-phase HPLC. Chromatography was performed as 
described in section 2. The detector was set at 210 nm. The bar repre- 
sents an absorbance of 0.01. (a) Separation of the biosynthesized dia- 
stereoisomers. A, L,D isomer; B, L,L isomer; (b) demonstration ofhomo- 
geneity of isolated B (L,D product); (c) decreased yield of B (L,D product) 
when [2-‘Hlvaline was used as a substrate (peaks C and D are ‘impuri- 
ties’ sometimes derived from the Dowex column chromatography). 
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AMp (L. D)-CYS-VAL-S-I 
Hz0 
Scheme 2. A revised mechanism for ACV synthetase. Abbreviations as 
for Scheme 1. 
niques. Furthermore, we have recovered the dipeptides from 
solution, whereas the dipeptides in actinomycin D biosynthesis 
were detected as enzyme-bound intermediates. This indicates 
that the enzyme can release the ‘incorrect’ dipeptide. The re- 
sults described clearly imply that the biosynthesis of ACV itself 
proceeds via an enzyme-bound cysteinyl-valine intermediate. 
Previous results (based on very sensitive radiochemical and 
bio-assays) [8,13] reporting very low conversion of L-b-(a-ami- 
noadipoyl)-L-cysteine and L-valine with ACV synthetase may 
seem to argue against the intermediacy of cysteinyl-vahne. 
However, in this case 6-L-(a-aminoadipoyl)-L-cysteine may act 
as a weak analogue of L-cysteine with epimerisation occurring 
at the tripeptide stage. Consistent with this hypothesis, we have 
observed that the authentic dipeptide L-&(a-aminoadipoyl)-L- 
cysteine stimulated ATP-PP, exchange significantly (36% the 
rate seen in response to cysteine) whereas authentic L,L- and 
L,o-cysteinyl-valine were effectively unable to stimulate the ex- 
change (~0.8% the rate seen with cysteine). 
This is the first report of incubations in vitro with a peptide 
synthetase leading to the isolation and unambiguous character- 
ization of an incomplete peptide product containing an L-amino 
acid residue at the same position as that occupied by a n-amino 
acid residue in the complete natural product. The isolation of 
both L-O-methylserinyl-L-valine and L-O-methylserinyl-o-val- 
ine indicates that the biosynthesis of ACV proceeds from the 
C- to the N-terminus with epimerisation occurring at either the 
di- or tripeptide stage. As a result of our observations we wish 
to propose a simpler revised mechanism for ACV synthetase 
(Scheme 2). This incorporates (a) formation of the a-peptide 
bond between cysteine and valine prior to (b) epimerisation of 
the valine residue in the intermediate dipeptide, followed by 
(c) formation of the peptide bond to the Ci-carboxyl of a-amino- 
adipate, and finally (d) release of the tripeptide from the en- 
zyme-bound 4’-phosphopantetheine by a thioesterase activity. 
Our results indicate also that the individual partial reactions in 
the synthesis of ACV have subtly distinct substrate specificities. 
They may thus act as a series of ‘gates’ which prevent incorpo- 
ration of some analogues into complete tripeptide products. 
That the ACV synthetase can release an ‘incorrect’ dipeptide 
intermediate into solution might indicate a form of editing by 
the peptide synthetase. 
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